Can you take Semaglutide and Tirzepatide together?

The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

Rankings / Comparisons

Semaglutide vs Tirzepatide

Single-agonist GLP-1 vs dual GLP-1/GIP — head-to-head weight loss data and side-effect profile.

Reviewed by Read Off Label · How we grade

Score comparison

Read Off Label's composite gives Semaglutide and Tirzepatide the same 6.8/10 score. Their separate Evidence, Benefit, and Safety axes show where their profiles differ.

Semaglutide

B 6.8/10

aka Ozempic, Wegovy, Rybelsus

Evidence: Strong (8/10)
Benefit: High (8/10)
Risk: Med (GI effects; gallbladder/pancreatitis; altered skin sensation more common at Wegovy HD 7.2 mg) (5/10 safety)
Legality: Rx
Dose / route context: Wegovy obesity label: titration to 2.4 mg SC weekly; Wegovy HD: 7.2 mg SC weekly in selected adults; Ozempic (T2DM): 0.25-2 mg SC weekly
Class: Prescription
Last reviewed: Jul 11, 2026

Read Off Label grades Semaglutide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

STEP 1: ~15% body weight loss over 68 weeks.

Studied, labeled, or reported-use context: Wegovy obesity label: titration to 2. — Rx; not individualized guidance.

What it is

STEP 1: ~15% body weight loss over 68 weeks. SELECT 2023: 20% reduction in MACE in obese patients with CVD but no diabetes. FDA approved Wegovy HD 7.2 mg on March 19, 2026 after data showed additional average weight reduction vs lower approved doses with a broadly consistent GLP-1 safety profile; altered skin sensation (sensitivity, pain, burning) was more common at the higher dose and is under further FDA investigation. GI side effects common; rare pancreatitis/gallbladder. Weight regain on cessation. Delayed gastric emptying raises peri-operative aspiration risk — anesthesia guidance now recommends holding GLP-1 agonists before elective surgery. Oral Wegovy (semaglutide tablets) is FDA-approved for chronic weight management; Phase 3 OASIS-4 (n=307, 64 wk): ~13.6% weight loss vs 2.4% placebo (treatment-policy estimand). A Jul 2026 BMJ network meta-analysis (262 RCTs, n=99,791) of approved anti-obesity drugs found subcutaneous semaglutide was the only agent in the comparison showing reduced all-cause mortality (RR 0.81) and MI (RR 0.72) -- an independent confirmation of the SELECT mortality signal.

Mechanism

GLP-1 receptor agonist: slows gastric emptying; suppresses glucagon; enhances glucose-dependent insulin secretion; central appetite suppression via hypothalamic GLP-1R

Full Semaglutide review →

Tirzepatide

B 6.8/10

aka Mounjaro, Zepbound

Evidence: Strong (8/10)
Benefit: High (most effective approved weight loss drug) (8/10)
Risk: Med (5/10 safety)
Legality: Rx
Dose / route context: Zepbound obesity label: titration to 10-15 mg SC weekly; Mounjaro (T2DM)
Class: Prescription
Last reviewed: Jul 11, 2026

Read Off Label grades Tirzepatide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

SURMOUNT-1: ~22.

Studied, labeled, or reported-use context: Zepbound obesity label: titration to 10-15 mg SC weekly; Mounjaro (T2DM) — Rx; not individualized guidance.

What it is

SURMOUNT-1: ~22.5% weight loss over 72 weeks at 15 mg — highest of any approved weight loss drug. SURMOUNT-5 (head-to-head 2025): tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks. SURPASS-CVOT showed CV non-inferiority to dulaglutide. SURMOUNT-1 176-week extension (Heerspink 2026, Diabetes Obes Metab) confirmed sustained weight loss and renal-function preservation. Awaiting SURMOUNT-MMO for CV outcomes in obesity without diabetes. A Jul 2026 BMJ network meta-analysis (262 RCTs, n=99,791) found tirzepatide lost the most fat mass of the approved anti-obesity drugs (-25.7%) but also the most lean mass (-8.3%) -- a composition trade-off not captured by weight-loss percentage alone.

Mechanism

Dual GIP/GLP-1 receptor agonist; GIP component enhances weight loss and glycemic effects beyond GLP-1 alone; mechanisms similar to semaglutide but more potent

Full Tirzepatide review →

Common questions

How do the evidence profiles of Semaglutide and Tirzepatide compare?: Read Off Label's composite gives Semaglutide and Tirzepatide the same 6.8/10 score. Their separate Evidence, Benefit, and Safety axes show where their profiles differ.
What's the difference between Semaglutide and Tirzepatide?: Single-agonist GLP-1 vs dual GLP-1/GIP — head-to-head weight loss data and side-effect profile.
Can you take Semaglutide and Tirzepatide together?: The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.